BMS-986012 in Relapsed/Refractory SCLC
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
- Status
- COMPLETED
- Phase
- PHASE3
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation
- Status
- COMPLETED
- Phase
- PHASE2
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)
- Status
- COMPLETED
- Phase
- PHASE2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
- Status
- COMPLETED
- Phase
- N/A
Expanded Access Program With Nivolumab to Treat Melanoma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
- Status
- TERMINATED
- Phase
- PHASE1
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
- Status
- COMPLETED
- Phase
- PHASE3
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
- Status
- COMPLETED
- Phase
- PHASE2
Immunotherapy Study for Patients With Stage IV Melanoma
- Status
- TERMINATED
- Phase
- PHASE2